Back to News

Spartan Bioscience receives FDA clearance for first rapid DNA test of mutations affecting metabolism of common drugs.

August 27th, 2013

Spartan Bioscience today announced that the US Food and Drug Administration (FDA) granted 510(k) clearance permitting marketing of the Spartan RX CYP2C19 System. It provides genetic results in less than 60 minutes from a non-invasive cheek swab.